Menu
Recruiting NCT05799898

Fast-Track Cardiovascular Assessment for Suspicion of Cardiovascular Events on Immunecheckpoint Inhibitors

— Observational Cancer Immune Checkpoint Inhibitor Cardiovascular Complication Immune-related Adverse Event

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: No intervention for research purposes only.
Who it may be relevant to
Registry conditions: Cancer, Immune Checkpoint Inhibitor, Cardiovascular Complication, Immune-related Adverse Event. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Fast-Track Cardiovascular Assessment for Suspicion of Cardiovascular Events on Immunecheckpoint Inhibitors: Prospective Cohort Study.

Overview

Prospective study cohort on patients addressed for suspected cardiovascular event on immune checkpoint inchibitors. Longitudinal prospective single center cohort. Inclusion criteria: all patient willing to particiupate seen in the cardio-oncology unit at our institution for the suspicion of heart failure, atherosclerosis related event, Tako Tsubo, arrhymias, pericarditis, myocarditis on antiPD1, antiPDL1, or antiCTLA4 immune checkpoint inhibitors. Description of patients characteristics, investigations, diagnosis after multidisciplinary meeting, outcomes.

Interventions

  • Other No intervention for research purposes only
    No intervention for research purposes only

Primary outcome measures

  • Major cardiovascular event [Time frame: 12 months]

Eligibility criteria

Inclusion criteria

  • all patient referred to the cardio oncology unit for suspected immune related cardiovascular complication on immune checkpoint inhibitors

Exclusion criteria

  • none

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

France · 1 center
  • Intitut Mutualiste Montsouris — Paris

Identifiers

NCT: NCT05799898 · CARDIO-03-2022

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗